Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab

Molecular Oncology

Volumn 7, Issue 3, 2013, Pages 580-594

  Mamidi, Srinivas ^a   Cinci, Marc ^a   Hasmann, Max ^b   Fehring, Volker ^c   Kirschfink, Michael ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

^c Silence Therapeutics GmbH   (Germany)

Author keywords

Complement regulatory proteins; Complement resistance; Lipoplex; Pertuzumab; SiRNA; Trastuzumab

Indexed keywords

CD59 ANTIGEN; DECAY ACCELERATING FACTOR; LIPOPLEX; MEMBRANE COFACTOR PROTEIN; PERTUZUMAB; SMALL INTERFERING RNA; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; OVARY ADENOCARCINOMA; PRIORITY JOURNAL;

EID: 84878107502     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.02.011     Document Type: Article

References (59)

1. Aagaard L., Rossi J.J. RNAi therapeutics: principles, prospects and challenges. Adv. Drug Deliv. Rev. 2007, 59:75-86.
2. Aleku M., Schulz P., Keil O., Santel A., Schaeper U., Dieckhoff B., Janke O., Endruschat J., Durieux B., Roder N., Loffler K., Lange C., Fechtner M., Mopert K., Fisch G., Dames S., Arnold W., Jochims K., Giese K., Wiedenmann B., Scholz A., Kaufmann J. Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res. 2008, 68:9788-9798.
3. Barok M., Isola J., Palyi-Krekk Z., Nagy P., Juhasz I., Vereb G., Kauraniemi P., Kapanen A., Tanner M., Szollosi J. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol. Cancer Ther. 2007, 6:2065-2072.
4. Baselga J., Cortes J., Kim S.B., Im S.A., Hegg R., Im Y.H., Roman L., Pedrini J.L., Pienkowski T., Knott A., Clark E., Benyunes M.C., Ross G., Swain S.M. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 2012, 366:109-119.
5. Bellone S., Roque D., Cocco E., Gasparrini S., Bortolomai I., Buza N., Abu-Khalaf M., Silasi D.A., Ratner E., Azodi M., Schwartz P.E., Rutherford T.J., Pecorelli S., Santin A.D. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy. Br. J. Cancer 2012, 106:1543-1550.
6. Boross P., Leusen J.H. Boosting antibody therapy with complement. Blood 2012, 119:5945-5947.
7. Borsos T., Circolo A. Binding and activation of C1 by cell bound IgG: activation depends on cell surface hapten density. Mol. Immunol. 1983, 20:433-438.
8. Burnett J.C., Rossi J.J. RNA-based therapeutics: current progress and future prospects. Chem. Biol. 2012, 19:60-71.
9. Castanotto D., Sakurai K., Lingeman R., Li H., Shively L., Aagaard L., Soifer H., Gatignol A., Riggs A., Rossi J.J. Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. Nucleic Acids Res. 2007, 35:5154-5164.
10. Clynes R.A., Towers T.L., Presta L.G., Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 2000, 6:443-446.
11. Cragg M.S., Howatt W.J., Bloodworth L., Anderson V.A., Morgan B.P., Glennie M.J. Complement mediated cell death is associated with DNA fragmentation. Cell. Death Differ. 2000, 7:48-58.
12. Czauderna F., Fechtner M., Dames S., Aygun H., Klippel A., Pronk G.J., Giese K., Kaufmann J. Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. 2003, 31:2705-2716.
13. Dechant M., Weisner W., Berger S., Peipp M., Beyer T., Schneider-Merck T., Lammerts van Bueren J.J., Bleeker W.K., Parren P.W., van de Winkel J.G., Valerius T. Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Res. 2008, 68:4998-5003.
14. Donin N., Jurianz K., Ziporen L., Schultz S., Kirschfink M., Fishelson Z. Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid. Clin. Exp. Immunol. 2003, 131:254-263.
15. Durrant L.G., Chapman M.A., Buckley D.J., Spendlove I., Robins R.A., Armitage N.C. Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients. Cancer Immunol. Immunother. 2003, 52:638-642.
16. Faratian D., Zweemer A.J., Nagumo Y., Sims A.H., Muir M., Dodds M., Mullen P., Um I., Kay C., Hasmann M., Harrison D.J., Langdon S.P. Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies. Clin. Cancer Res. 2011, 17:4451-4461.
17. Felgner P.L., Gadek T.R., Holm M., Roman R., Chan H.W., Wenz M., Northrop J.P., Ringold G.M., Danielsen M. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. U.S.A. 1987, 84:7413-7417.
18. Fishelson Z., Donin N., Zell S., Schultz S., Kirschfink M. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol. Immunol. 2003, 40:109-123.
19. Franklin M.C., Carey K.D., Vajdos F.F., Leahy D.J., de Vos A.M., Sliwkowski M.X. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004, 5:317-328.
20. Gancz D., Fishelson Z. Cancer resistance to complement-dependent cytotoxicity (CDC): problem-oriented research and development. Mol. Immunol. 2009, 46:2794-2800.
21. Geis N., Zell S., Rutz R., Li W., Giese T., Mamidi S., Schultz S., Kirschfink M. Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro. Curr. Cancer Drug Targets 2010, 10:922-931.
22. Gelderman K.A., Tomlinson S., Ross G.D., Gorter A. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol. 2004, 25:158-164.
23. Golay J., Cittera E., Di Gaetano N., Manganini M., Mosca M., Nebuloni M., van Rooijen N., Vago L., Introna M. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica 2006, 91:176-183.
24. Hellstrom I., Goodman G., Pullman J., Yang Y., Hellstrom K.E. Overexpression of HER-2 in ovarian carcinomas. Cancer Res. 2001, 61:2420-2423.
25. Hirsch F.R., Franklin W.A., Veve R., Varella-Garcia M., Bunn P.A. HER2/neu expression in malignant lung tumors. Semin. Oncol. 2002, 29:51-58.
26. Judge A.D., Bola G., Lee A.C., MacLachlan I. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol. Ther. 2006, 13:494-505.
27. Jurianz K., Ziegler S., Donin N., Reiter Y., Fishelson Z., Kirschfink M. K562 erythroleukemic cells are equipped with multiple mechanisms of resistance to lysis by complement. Int. J. Cancer 2001, 93:848-854.
28. Jurianz K., Ziegler S., Garcia-Schuler H., Kraus S., Bohana-Kashtan O., Fishelson Z., Kirschfink M. Complement resistance of tumor cells: basal and induced mechanisms. Mol. Immunol. 1999, 36:929-939.
29. Klausz K., Berger S., Lammerts van Bueren J.J., Derer S., Lohse S., Dechant M., van de Winkel J.G., Peipp M., Parren P.W., Valerius T. Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII). Cancer Sci. 2011, 102:1761-1768.
30. Klein E., Di Renzo L., Yefenof E. Contribution of CR3, CD11b/CD18 to cytolysis by human NK cells. Mol. Immunol. 1990, 27:1343-1347.
31. Kojima A., Iwata K., Seya T., Matsumoto M., Ariga H., Atkinson J.P., Nagasawa S. Membrane cofactor protein (CD46) protects cells predominantly from alternative complement pathway-mediated C3-fragment deposition and cytolysis. J. Immunol. 1993, 151:1519-1527.
32. Koller E., Propp S., Murray H., Lima W., Bhat B., Prakash T.P., Allerson C.R., Swayze E.E., Marcusson E.G., Dean N.M. Competition for RISC binding predicts in vitro potency of siRNA. Nucleic Acids Res. 2006, 34:4467-4476.
33. Kzhyshkowska J., Mamidi S., Gratchev A., Kremmer E., Schmuttermaier C., Krusell L., Haus G., Utikal J., Schledzewski K., Scholtze J., Goerdt S. Novel stabilin-1 interacting chitinase-like protein (SI-CLP) is up-regulated in alternatively activated macrophages and secreted via lysosomal pathway. Blood 2006, 107:3221-3228.
34. Leidi M., Gotti E., Bologna L., Miranda E., Rimoldi M., Sica A., Roncalli M., Palumbo G.A., Introna M., Golay J. M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. J. Immunol. 2009, 182:4415-4422.
35. Li B., Allendorf D.J., Hansen R., Marroquin J., Ding C., Cramer D.E., Yan J. Yeast beta-glucan amplifies phagocyte killing of iC3b-opsonized tumor cells via complement receptor 3-Syk-phosphatidylinositol 3-kinase pathway. J. Immunol. 2006, 177:1661-1669.
36. Macor P., Mezzanzanica D., Cossetti C., Alberti P., Figini M., Canevari S., Tedesco F. Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma. Cancer Res. 2006, 66:3876-3883.
37. Macor P., Tripodo C., Zorzet S., Piovan E., Bossi F., Marzari R., Amadori A., Tedesco F. In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res. 2007, 67:10556-10563.
38. Manches O., Lui G., Chaperot L., Gressin R., Molens J.P., Jacob M.C., Sotto J.J., Leroux D., Bensa J.C., Plumas J. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003, 101:949-954.
39. Medof M.E., Kinoshita T., Nussenzweig V. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J. Exp. Med. 1984, 160:1558-1578.
40. Meri S., Morgan B.P., Davies A., Daniels R.H., Olavesen M.G., Waldmann H., Lachmann P.J. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 1990, 71:1-9.
41. Molina M.A., Codony-Servat J., Albanell J., Rojo F., Arribas J., Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 2001, 61:4744-4749.
42. Nahta R., Hung M.C., Esteva F.J. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 2004, 64:2343-2346.
43. Nauta A.J., Daha M.R., Tijsma O., van de Water B., Tedesco F., Roos A. The membrane attack complex of complement induces caspase activation and apoptosis. Eur. J. Immunol. 2002, 32:783-792.
44. Owens M.A., Horten B.C., Da Silva M.M. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin. Breast Cancer 2004, 5:63-69.
45. Santel A., Aleku M., Keil O., Endruschat J., Esche V., Durieux B., Loffler K., Fechtner M., Rohl T., Fisch G., Dames S., Arnold W., Giese K., Klippel A., Kaufmann J. RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy. Gene Ther. 2006, 13:1360-1370.
46. Santel A., Aleku M., Keil O., Endruschat J., Esche V., Fisch G., Dames S., Loffler K., Fechtner M., Arnold W., Giese K., Klippel A., Kaufmann J. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther. 2006, 13:1222-1234.
47. Santel A., Aleku M., Roder N., Mopert K., Durieux B., Janke O., Keil O., Endruschat J., Dames S., Lange C., Eisermann M., Loffler K., Fechtner M., Fisch G., Vank C., Schaeper U., Giese K., Kaufmann J. Atu027 prevents pulmonary metastasis in experimental and spontaneous mouse metastasis models. Clin. Cancer Res. 2010, 16:5469-5480.
48. Scheuer W., Friess T., Burtscher H., Bossenmaier B., Endl J., Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009, 69:9330-9336.
49. Shepard H.M., Lewis G.D., Sarup J.C., Fendly B.M., Maneval D., Mordenti J., Figari I., Kotts C.E., Palladino M.A., Ullrich A., et al. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J. Clin. Immunol. 1991, 11:117-127.
50. Teeling J.L., French R.R., Cragg M.S., van den Brakel J., Pluyter M., Huang H., Chan C., Parren P.W., Hack C.E., Dechant M., Valerius T., van de Winkel J.G., Glennie M.J. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004, 104:1793-1800.
51. Treon S.P., Mitsiades C., Mitsiades N., Young G., Doss D., Schlossman R., Anderson K.C. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with b-cell malignancies. J. Immunother. (1991) 2001, 24:263-271.
52. Varsano S., Rashkovsky L., Shapiro H., Ophir D., Mark-Bentankur T. Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance. Clin. Exp. Immunol. 1998, 113:173-182.
53. Vetvicka V., Thornton B.P., Wieman T.J., Ross G.D. Targeting of natural killer cells to mammary carcinoma via naturally occurring tumor cell-bound iC3b and beta-glucan-primed CR3 (CD11b/CD18). J. Immunol. 1997, 159:599-605.
54. Walport M.J. Complement. First of two parts. N. Engl. J. Med. 2001, 344:1058-1066.
55. Watson N.F., Durrant L.G., Madjd Z., Ellis I.O., Scholefield J.H., Spendlove I. Expression of the membrane complement regulatory protein CD59 (protectin) is associated with reduced survival in colorectal cancer patients. Cancer Immunol. Immunother. 2006, 55:973-980.
56. Weiner L.M., Surana R., Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 2010, 10:317-327.
57. Yan J., Allendorf D.J., Li B., Yan R., Hansen R., Donev R. The role of membrane complement regulatory proteins in cancer immunotherapy. Adv. Exp. Med. Biol. 2008, 632:159-174.
58. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol. 2001, 2:127-137.
59. Zell S., Geis N., Rutz R., Schultz S., Giese T., Kirschfink M. Down-regulation of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides (S-ODNs) sensitizes tumour cells to complement attack. Clin. Exp. Immunol. 2007, 150:576-584.